Description |
R667 is an orally active, gamma selective retinoid agonist that shows promise as a treatment for emhysema, as it has, in animal models, promoted structural lung repair and functional improvement with fewer side effects. It is currently in Phase II Trials for emphysema secondary to alpha-1 antitrypsin
deficiency.
|
